Literature DB >> 3391142

gamma-Hydroxybutyrate model of generalized absence seizures: further characterization and comparison with other absence models.

O C Snead1.   

Abstract

gamma-Hydroxybutyrate (GHB) produces a constellation of EEG and behavioral events that respond selectively to antiabsence antiepileptic drugs. The GHB-induced seizure was quantitated in the presence of three other absence seizure models: pentylenetetrazole, systemic penicillin, and the flash evoked afterdischarge (FEAD). Penicillin and pentylenetetrazole produced a significant prolongation of GHB-induced seizure in a dose-dependent fashion. This potentiation of GHB seizure was observed when these compounds were given either before administration of gamma-butyrolactone (GBL), the prodrug of GHB, or at the onset of GHB-induced seizure. Photic stimulation given in a manner to produce FEAD also resulted in a significant prolongation of GHB-induced seizure. All of these maneuvers lowered the threshold to GHB seizure, but none interfered with the brain kinetics of GHB in the animals treated with GBL. Ethosuximide pretreatment significantly shortened the GHB seizure and overcame the potentiating effect of penicillin and pentylenetetrazole in this model. These data confirm the GHB-treated animal as a model of generalized absence seizure. The GHB model meets appropriate criteria for an absence seizure model and compares favorably with other models of absence currently in use.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391142     DOI: 10.1111/j.1528-1157.1988.tb03732.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  20 in total

1.  Modulation of absence seizures by the GABA(A) receptor: a critical rolefor metabotropic glutamate receptor 4 (mGluR4).

Authors:  O C Snead; P K Banerjee; M Burnham; D Hampson
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Another health food hazard--gamma-hydroxybutyrate-induced seizures.

Authors:  B T Adornato; V Tse
Journal:  West J Med       Date:  1992-10

3.  A gain in GABAA receptor synaptic strength in thalamus reduces oscillatory activity and absence seizures.

Authors:  Claude M Schofield; Max Kleiman-Weiner; Uwe Rudolph; John R Huguenard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-20       Impact factor: 11.205

4.  Hyperexcitability of rat thalamocortical networks after exposure to general anesthesia during brain development.

Authors:  Michael R DiGruccio; Srdjan Joksimovic; Pavle M Joksovic; Nadia Lunardi; Reza Salajegheh; Vesna Jevtovic-Todorovic; Mark P Beenhakker; Howard P Goodkin; Slobodan M Todorovic
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

5.  Impact of strain, sex, and estrous cycle on gamma butyrolactone-evoked absence seizures in rats.

Authors:  Victor R Santos; Ihori Kobayashi; Robert Hammack; Gregory Danko; Patrick A Forcelli
Journal:  Epilepsy Res       Date:  2018-09-18       Impact factor: 3.045

6.  Corticothalamic modulation during absence seizures in rats: a functional MRI assessment.

Authors:  Jeffrey R Tenney; Timothy Q Duong; Jean A King; Reinhold Ludwig; Craig F Ferris
Journal:  Epilepsia       Date:  2003-09       Impact factor: 5.864

Review 7.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

8.  Aspartame and seizures.

Authors:  P C Jobe; J W Dailey
Journal:  Amino Acids       Date:  1993-10       Impact factor: 3.520

Review 9.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

10.  The hippocampus participates in a pharmacological rat model of absence seizures.

Authors:  Justin Arcaro; Jingyi Ma; Liangwei Chu; MinChing Kuo; Seyed M Mirsattari; L Stan Leung
Journal:  Epilepsy Res       Date:  2015-12-24       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.